Combination therapy of all-trans retinoic acid with ursodeoxycholic acid in patients with primary sclerosing cholangitis: A human pilot study

David N. Assis, Osama Abdelghany, Shi Ying Cai, Andrea A. Gossard, John E. Eaton, Jill C. Keach, Yanhong Deng, Kenneth D R Setchell, Maria Ciarleglio, Keith Lindor, James L. Boyer

Research output: Contribution to journalArticle

16 Scopus citations

Abstract

Goals: To perform an exploratory pilot study of all-trans retinoic acid (ATRA) combined with ursodeoxycholic acid (UDCA) in patients with primary sclerosing cholangitis (PSC). Background: PSC is a progressive disorder for which there is no accepted therapy. Studies in human hepatocyte cultures and in animal models of cholestasis indicate that ATRA might have beneficial effects in cholestatic disorders. Study: ATRA (45mg/m2/d, divided and given twice daily) was combined with moderate-dose UDCA in patients with PSC who had incomplete response to UDCA monotherapy. The combination was administered for 12 weeks, followed by a 12-week washout in which patients returned to UDCA monotherapy. We measured alkaline phosphatase (ALP), alanine aminotransferase (ALT), bilirubin, cholesterol, bile acids, and the bile acid intermediate 7a-hydroxy-4- cholesten-3-one (C4) at baseline, week 12, and after washout. Results: Fifteen patients completed 12 weeks of therapy. The addition of ATRA to UDCA reduced the median serum ALP levels (277±211 to 243±225U/L, P=0.09) although this, the primary endpoint, did not reach significance. In contrast, median serum ALT (76±55 to 46±32U/L, P=0.001) and C4 (9.8±19 to 7.9±11 ng/ mL, P=0.03) levels significantly decreased. After washout, ALP and C4 levels nonsignificantly increased, whereas ALT levels significantly increased (46±32 to 74±74, P=0.0006), returning to baseline. Conclusions: In this human pilot study, the combination of ATRA and UDCA did not achieve the primary endpoint (ALP); however, it significantly reduced ALT and the bile acid intermediate C4. ATRA appears to inhibit bile acid synthesis and reduce markers of inflammation, making it a potential candidate for further study in PSC (NCT 01456468).

Original languageEnglish (US)
Pages (from-to)e11-e16
JournalJournal of Clinical Gastroenterology
Volume51
Issue number2
DOIs
StatePublished - Jan 1 2017

Keywords

  • All-trans retinoic acid
  • Clinical trial
  • FXR
  • Primary sclerosing cholangitis
  • RXR

ASJC Scopus subject areas

  • Gastroenterology

Fingerprint Dive into the research topics of 'Combination therapy of all-trans retinoic acid with ursodeoxycholic acid in patients with primary sclerosing cholangitis: A human pilot study'. Together they form a unique fingerprint.

  • Cite this

    Assis, D. N., Abdelghany, O., Cai, S. Y., Gossard, A. A., Eaton, J. E., Keach, J. C., Deng, Y., Setchell, K. D. R., Ciarleglio, M., Lindor, K., & Boyer, J. L. (2017). Combination therapy of all-trans retinoic acid with ursodeoxycholic acid in patients with primary sclerosing cholangitis: A human pilot study. Journal of Clinical Gastroenterology, 51(2), e11-e16. https://doi.org/10.1097/MCG.0000000000000591